Home » Stocks » NBRV

Nabriva Therapeutics PLC (NBRV)

Stock Price: $2.92 USD -0.13 (-4.26%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 61.55M
Revenue (ttm) 2.90M
Net Income (ttm) -74.70M
Shares Out 14.47M
EPS (ttm) -6.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $2.92
Previous Close $3.05
Change ($) -0.13
Change (%) -4.26%
Day's Open 3.09
Day's Range 2.77 - 3.08
Day's Volume 901,879
52-Week Range 2.37 - 16.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developmen...

GlobeNewsWire - 1 month ago

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developmen...

GlobeNewsWire - 1 month ago

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developmen...

GlobeNewsWire - 1 month ago

- Amen ded agreement encompasses enhanced manufacturing collaboration and regulatory support

GlobeNewsWire - 2 months ago

DUBLIN, Ireland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infe...

Seeking Alpha - 2 months ago

Nabriva Therapeutics plc's (NBRV) CEO Ted Schroeder on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

-Relaunch of Xenleta® and Sivextro® commenced in late September-  

GlobeNewsWire - 2 months ago

DUBLIN, Ireland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infe...

GlobeNewsWire - 3 months ago

-- Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at...

GlobeNewsWire - 4 months ago

-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship

Seeking Alpha - 5 months ago

Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

DUBLIN, Ireland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-in...

GlobeNewsWire - 5 months ago

DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-in...

Zacks Investment Research - 5 months ago

Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

GlobeNewsWire - 5 months ago

- XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years

GlobeNewsWire - 5 months ago

-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone

GlobeNewsWire - 6 months ago

-XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc. -XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc.

Zacks Investment Research - 6 months ago

Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.

GlobeNewsWire - 6 months ago

DUBLIN, Ireland and KING OF PRUSSIA, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developm...

GlobeNewsWire - 6 months ago

Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities Agency Cited Travel Restrictions and Inability to Condu...

Zacks Investment Research - 7 months ago

Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.

GlobeNewsWire - 7 months ago

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developme...

GlobeNewsWire - 7 months ago

Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS com...

Seeking Alpha - 8 months ago

Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire - 8 months ago

Results support Xenleta as an empiric, short-course monotherapy replacement for respiratory fluoroquinolones for treatment of CABP Results support Xenleta as an empiric, short-course monothera...

Zacks Investment Research - 9 months ago

Nabriva Therapeutics (NBRV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

GlobeNewsWire - 9 months ago

DUBLIN, Ireland, April 09, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-i...

GlobeNewsWire - 9 months ago

DUBLIN, Ireland, April 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-i...

Zacks Investment Research - 9 months ago

Nabriva (NBRV) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Seeking Alpha - 10 months ago

Nabriva Therapeutics' (NBRV) CEO Ted Schroeder on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

DUBLIN, Ireland, March 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-i...

GlobeNewsWire - 11 months ago

DUBLIN, Ireland, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-in...

Zacks Investment Research - 11 months ago

As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.

GlobeNewsWire - 1 year ago

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and developm...

Market Watch - 1 year ago

Shares of Nabriva Therapeutics PLC NBRV, -3.37% soared 10.5% in premarket trading Friday, after the biotechnology company said it resubmitted its new drug application (NDA) for Contepo, its tr...

GlobeNewsWire - 1 year ago

-Nabriva anticipates a six-month review period by the Food and Drug Administration

GlobeNewsWire - 1 year ago

DUBLIN, Ireland, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-in...

Benzinga - 1 year ago

Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) shares have gained about 46% year-to-date.

Seeking Alpha - 1 year ago

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q3 2019 Results - Earnings Call Transcript

InvestorPlace - 1 year ago

Investors want to know which stocks are set to take flight. We are talking about stocks with serious growth prospects here, or names that can more than double investors’ returns in the next year.

Other stocks mentioned: ATNX, DVAX, FTCH, HRVSF, SNDL
GlobeNewsWire - 1 year ago

Poster sessions to highlight pooled results from the pivotal LEAP 1 and LEAP 2 Phase 3 clinical trials Poster sessions to highlight pooled results from the pivotal LEAP 1 and LEAP 2 Phase 3 cl...

GlobeNewsWire - 1 year ago

Nabriva publication of Phase 3 clinical trial results highlights efficacy of XENLETA™ (lefamulin tablets) as novel, short-course, empiric monotherapy for adults with community-acquired bacteri...

GlobeNewsWire - 1 year ago

DUBLIN, Ireland, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-i...

Seeking Alpha - 1 year ago

Today, we look at Nabriva Therapeutics which has received a tepid reception for the FDA approval of its antibiotic Xenleta on August 19th, 2019.

GlobeNewsWire - 1 year ago

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and develop...

GlobeNewsWire - 1 year ago

First IV and oral antibiotic with novel mechanism of action approved by the FDA in nearly two decades, targets the most common CABP pathogens and supports antibiotic stewardship First IV and o...

GlobeNewsWire - 1 year ago

DUBLIN, Ireland, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-i...

About NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint... [Read more...]

Industry
Biotechnology
IPO Date
Sep 18, 2015
CEO
Theodore Schroeder
Employees
162
Stock Exchange
NASDAQ
Ticker Symbol
NBRV
Full Company Profile

Financial Performance

In 2019, NBRV's revenue was $9.48 million, a decrease of -1.81% compared to the previous year's $9.66 million. Losses were -$82.76 million, -27.89% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for NBRV stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 208.22% from the latest price.

Price Target
$9.00
(208.22% upside)
Analyst Consensus: Buy